retatrutide clinical trial dose VisualAbstract: reduces body weight by 17.5% in patients with obesity ESC 2024: Retatrutide improves lipid

For overweight individuals, muscle loss (sarcopenic obesity) is a genuine concern

DOSAGE AND ADMINISTRATION : DOSAGE FORMS AND STRENGTHS : Solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg (6 mg/mL, 3 mL) CONTRAINDICATIONS : Do not use in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2

For people with type 1 diabetes, GLP-1 and GIP medications may offer meaningful benefits

D., Smith, P., Ferguson, A

GLP 1 therapy supports a healthier internal environment

A BMI over 25 is considered overweight, and a reading of 30 or higher is classified as obese